martes, 20 de marzo de 2018

Genetics of Breast and Gynecologic Cancers (PDQ®)—Health Professional Version - National Cancer Institute

Genetics of Breast and Gynecologic Cancers (PDQ®)—Health Professional Version - National Cancer Institute
National Cancer Institute

Genetics of Breast and Gynecologic Cancers (PDQ®)–Health Professional Version


Changes to This Summary (03/12/18)

The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.
Updated National Comprehensive Cancer Network (NCCN) as reference 93.
Added text to state that a case-control study from Belarus and Germany looked at the most common pathogenic variant in RECQL and found it to be linked to estrogen receptor–positive breast cancer. The odds ratio (OR) in this study alone was 1.23, but in a meta-analysis with a Polish study, the OR was 2.51 (cited Bogdanova et al. as reference 90).
Revised text to state that the NCCN currently recommends annual breast magnetic resonance imaging (MRI) screening between ages 25 and 29 years and annual breast MRI and mammography (with consideration of tomosynthesis) between ages 30 and 75 years for BRCApathogenic variant carriers (cited NCCN as reference 33).
The Risk-reducing mastectomy subsection was extensively revised.
Added text to state that other studies have shown that physician referral of patients who meet U.S. Preventive Services Task Force guidelines for BRCA genetic counseling has been suboptimal (cited Bellcross et al. as reference 22).
Added text to state that the uptake of BRCA testing to inform surgical treatment decisions when offered appears to be high in research cohorts; however, findings from other studies suggest that testing is underutilized in clinical practice to inform breast cancer treatment decisions (cited Schwartz et al., Levy et al., Weitzel et al., Kurian et al., and Childers et al. as references 2, 6, 23, 24, and 25, respectively). Also, added text to state that barriers to the use of BRCA testing to inform surgical treatment decisions, including lack of physician referral of newly diagnosed patients for genetic counseling, type of insurance coverage, and challenges in the timing and coordination of testing, have been reported (cited Pal et al., Weldon et al., and Hafertepen et al. as references 26, 27, and 28, respectively).
This summary is written and maintained by the PDQ Cancer Genetics Editorial Board, which is editorially independent of NCI. The summary reflects an independent review of the literature and does not represent a policy statement of NCI or NIH. More information about summary policies and the role of the PDQ Editorial Boards in maintaining the PDQ summaries can be found on the About This PDQ Summary and PDQ® - NCI's Comprehensive Cancer Database pages.
  • Updated: March 12, 2018

No hay comentarios:

Publicar un comentario